At present, many pharmaceutical companies are facing problems such as competition for R&D resources and overcapacity, and actions such as selling assets and stopping pipelines have also occurred
.
It is reported that recently, pharmaceutical companies have frequently sold assets
.
For example, Harbour Biopharma announced on November 15 that it would sell the production plant of its Biomacromolecule R&D Innovation Center project to WuXi Hyde, a subsidiary of Biologics Biologics, for a transaction price of 146 million yuan
.
For the sale, Harbour Biologics said it aims to monetize assets under construction, reduce operating costs, reallocate property and other resources to drug development, invest in projects with growth prospects and more stable revenues, and establish a long-term strategic relationship
with WuXi Biologics.
It is worth noting that this is not the first time that Harbour Pharma has "broken arm" self-insurance
.
On November 11, Harbour Biopharma announced that it sold HCAb, a fully human heavy-chain antibody platform of its wholly-owned subsidiary Nona Biologics, to Moderna
.
In addition, last month, Harbour Pharma issued two consecutive announcements, announcing that it had licensed its late-stage clinical batory (FcRn monoclonal mab) to Enbipu Pharmaceutical Co.
, Ltd.
, a subsidiary of CSPC Pharmaceutical Group; At the same time, it ended its phase III clinical trial of tenacercept (HBM9036) in China and no new subjects
were enrolled.
Recently, ST Guodan also issued an announcement that Jiangsu Guodan Biopharmaceutical Co.
, Ltd.
intends to sell part of its assets, API production workshop assets, to Jiangsu Yingke Biopharmaceutical Co.
, Ltd.
The company said that after the completion of this sale, it is conducive to optimizing the company's asset structure
.
In the long term, reducing fixed costs and finance expenses has a positive impact
on the company's future financial position.
Jingfeng Pharmaceutical also recently announced that according to the needs of the company's business and strategic development, Shanghai Jingfeng, a wholly-owned subsidiary of the company, intends to sell its real estate located in Lane 868, Puming Road, Pudong New Area, Shanghai, with a total construction area of 701.
63 square meters, to Yue Hongwei, a natural person, at a transaction price of 120 million yuan
.
Regarding the sale of real estate, Jingfeng Pharmaceutical said that the sale is in line with the company's business development strategy plan, which is conducive to further improving management efficiency, reducing management costs, facilitating centralized management, and sustainable development of the company, and bringing positive impact
on the company's future financial status and operating results.
Judging from the current market situation, the sale of assets by pharmaceutical companies has occurred
frequently.
In addition to selling assets, pharmaceutical companies are keen to shut down pipelines to reduce operating costs and develop more valuable pipelines
, the industry said.
Hutchison recently announced that it is actively making a strategic shift to focus on drugs that are cutting-edge in its in-house pipeline that have the potential to drive near-term value
。 According to the announcement of Hutchison Pharmaceutical, the company's strategic adjustments mainly include: prioritizing its late-stage registration studies and approval of these drugs for the marketing of these drugs through regulatory authorities, especially the global registration of fruquintinib; Some early-stage research will no longer be prioritized for internal development, while certain other projects will consider external business opportunities; Seek potential partners to commercialize their drugs outside of China; Streamline your organization, redeploy key talent to support registration studies, regulatory filings, and more
.
It is reported that the same "test" is also Cornerstone Pharmaceutical
.
On November 15, CStone explained the rumors that "CStone Suzhou plant stopped production and stopped production", saying that considering that the Suzhou plant is still in the trial operation stage and there is no clear large-scale production demand in the near future, in order to reduce the company's operating costs, the Suzhou plant has temporarily stopped trial operation
in early November.
The industry said that from the current market situation, the experience of pharmaceutical companies similar to the above continues to be staged
.
The industry also said that at present, more and more pharmaceutical companies have a sharp increase in cash pressure, and many pharmaceutical companies have a short period of
money-burning years.
In addition to selling assets and shutting down pipelines, some companies are also reducing pressure through financing, layoffs, etc.
, so that they can focus on driving more valuable product pipeline development
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
